Mainstay Medical
-
Spine
Mainstay Medical Announces New ICD-10 Diagnostic Code for Multifidus Muscle Dysfunction
DUBLIN, October 3, 2024 –( BUSINESS WIRE )– Mainstay Medical announced today that the U.S. Centers for Disease Control and Prevention (CDC)…
Read More » -
Neuro
Mainstay Medical Announces Receipt of European and Australian Approvals of MRI Labeling on ReActiv8® Restorative Neurostimulation System™
MRI clearances received in connection with certification of conformity with EU and UK Medical Device Regulations DUBLIN, July 9, 2024–(BUSINESS…
Read More » -
Spine
Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up
Groundbreaking ReActiv8-B study supports the long-term efficacy, safety and durability of ReActiv8® Restorative NeurostimulationTM for the treatment of intractable Chronic Low…
Read More » -
Financial
Mainstay Medical Announces US$125 Million Equity Financing Transaction
Funding to accelerate commercial growth and expand clinical and health economic evidence for ReActiv8® Restorative Neuromodulation™ System DUBLIN, February 26, 2024…
Read More » -
Neuro
Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation System™
U.S. patients implanted with ReActiv8 now eligible for full-body MRI scans DUBLIN, February 12, 2024–(BUSINESS WIRE)–Mainstay Medical Holdings plc today…
Read More » -
Neuro
Mainstay Medical Announces Completion of Enrollment of RESTORE Clinical Trial of ReActiv8® in the United States
Randomized controlled clinical trial expected to validate effectiveness of ReActiv8® Restorative NeurostimulationTM vs. optimal medical management DUBLIN, August 29, 2023–(BUSINESS WIRE)–Mainstay Medical…
Read More » -
Spine
Mainstay Medical Announces Publication of Three-Year Clinical Trial Data from Post-Market Clinical Follow-up Registry of ReActiv8® in the United Kingdom
Further real-world evidence supporting the efficacy and use of ReActiv8® Restorative NeurostimulationTM for the treatment of intractable Chronic Low Back Pain…
Read More » -
Neuro
Mainstay Medical announces the release of post-marketing data from the ongoing ReActiv8®-C study in patients with chronic low back pain
New real-world findings support the effectiveness and use of ReActiv8® Restorative Neurostimulation™ to treat intractable chronic low back pain November…
Read More » -
Neuro
Mainstay Medical Announces Publication of Three-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™
Data continue to show compelling efficacy and safety, including improvement on all key measures of pain and disability, as compared…
Read More » -
Spine
Mainstay Medical Announces Publication of Two-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™
Data shows compelling efficacy and safety, as well as improvement on all key measures of pain and disability as compared…
Read More » -
Neuro
Mainstay Medical Announces Commercial Launch of ReActiv8® in Australia
March 8, 2021 DUBLIN–(BUSINESS WIRE)–Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced the commercial launch in Australia of…
Read More » -
Financial
Mainstay Medical Announces US$108 Million Equity Financing Transaction
Funding to support U.S. commercial launch and global expansion Dublin – Ireland, 16 February 2021 – Mainstay Medical Holdings plc…
Read More » -
Neuro
Mainstay Medical Announces Key Strategic Hires to Drive Global Commercial Expansion
January 25, 2021 DUBLIN–(BUSINESS WIRE)–Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced recent senior leadership additions as part…
Read More » -
Neuro
Mainstay Medical Announces U.S. FDA Approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain
June 22, 2020 DUBLIN–(BUSINESS WIRE)–Mainstay Medical Holdings plc (“Mainstay” or the “Company”) today announced that the U.S. Food and Drug…
Read More » -
Spine
Mainstay Medical to Showcase ReActiv8 and Key Clinical Data at the 13th German Spine Congress of the DWG
December 03, 2018 DUBLIN–(BUSINESS WIRE)–Regulatory News: Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Dublin:…
Read More »